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Abstract
Background Adherence to (non)pharmacological treatment
is important in heart failure (HF) patients, since it leads to
better clinical outcome. Although self-reported and objec-
tively measured medication adherence in HF patients have
been compared in previous studies, none of these studies
have used an evidence-based cutpoint to differentiate be-
tween adherence and non-adherence.
Methods In 37 HF patients (mean age 68±10 years, 27 %
female, 40 % NYHA functional class III-IV), medication
(ACEi/ARB) adherence was objectively measured using the
Medication Event Monitoring System (MEMS). Adherence
to and importance of taking medication was also assessed by
self-report using the Revised HF Compliance Questionnaire.
Results All patients reported that adherence was (highly)
important to them and that they ‘always’ took their medica-
tion as prescribed (i.e. 100 % adherence). However, when
measured by the MEMS, only 76 % of all patients were
adherent. Non-adherent patients more often had a complex
medication regimen (78 % vs. 21 %, P<.01), more often
depressive symptoms (75 % vs. 29 %, P0.04) and a shorter
history of HF (8 vs. 41 months, P0.04), compared with
adherent patients.
Conclusions Medication adherence measured by the
MEMS was remarkably lower than self-reported adherence.
Given the evidence of its importance, further efforts are
needed to improve adherence to the pharmacological regi-
men in HF patients.
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Introduction
Adherence to the pharmacological regimen and non-
pharmacological lifestyle changes is an important issue in
heart failure (HF). Adherence, defined as ‘the extent to
which the behaviour corresponds with agreed recommenda-
tions from a healthcare provider [1]’, leads to better outcome
in HF patients [2–4]. As a result of improvement in treat-
ment in the last decade, the HF regimen is becoming in-
creasingly complicated. According to international
guidelines, multiple medication should be prescribed at an
optimal dose [5], leading to a reduction in hospitalisations
[6]. However, drugs do not work in patients who do not take
them. Medication adherence in HF patients is not optimal,
with rates ranging from 10% to 96 % [7, 8], depending on
measurement and definition of adherence. Important factors
associated with adherence are socioeconomic status, symp-
tom severity, depression, complexity and costs of the regi-
men, perceived benefits and side effects [8, 9].
The importance of medication adherence has been recog-
nised and is therefore well established in the current litera-
ture. However, it is difficult to come to a general conclusion
about medication adherence due to methodological issues in
previous studies [8]. Firstly, adherence in previous studies
was measured using self-report and a variety of more ob-
jective measures, such as pharmacy refill and the medication
event monitoring system (MEMS). Self-report is a widely
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accepted and applied method to assess medication adher-
ence, however, this may be less reliable to fully reflect true
adherence. Secondly, in most studies on medication adher-
ence, the rationale of choosing a cutpoint to define adher-
ence in order to differentiate between adherence and non-
adherence was either not given or arbitrarily chosen. This
cutpoint differed per study, which may also have resulted in
different reported adherence rates. Given the importance of
adherence, using an evidence-based cutpoint seems to be a
crucial aspect in studying adherence with respect to clinical
relevance. An evidence-based cutpoint not only reflects
(non)adherence, but also identifies those patients with an
increased risk of adverse outcomes.
Although medication adherence objectively measured by
MEMS registration has been compared with self-reported
adherence in previous studies [3, 10], none of these studies
have used an evidence-based cutpoint to differentiate be-
tween objectively measured adherence and non-adherence.
Therefore, the aims of this study were to describe differ-
ences in self-reported and objectively measured medication
adherence by the MEMS based on an evidence-based cut-
point in a HF population and to assess differences between
adherent and non-adherent patients.
Methods
A subsample of 37 patients participating in the COACH
(Coordinating study evaluating Outcomes of Advising and
Counselling in Heart failure patients) study [11, 12] was
analysed. The main objective of COACH was to evaluate
the effect of a moderate or intense nurse-led disease man-
agement program on clinical outcome in HF patients. At
baseline, patients were randomly assigned to a control (care
as usual) or an intervention group (basic or intensive sup-
port) and were followed during a fixed, 18-month period
after discharge. Along with the routine management by the
cardiologist, patients in both intervention groups received
additional care from an HF nurse which consisted of com-
prehensive education and counselling about HF and the
regimen at baseline and during follow-up, according to
protocol. The study complied with the Declaration of Hel-
sinki and the Medical Ethics Committee granted approval
for the protocol.
For this substudy, longitudinal data on medication adher-
ence collected during COACH were used. Adherence to
ACE inhibitors (ACEi) or angiotensin receptor blockers
(ARB) was measured using the Medication Event Monitor-
ing System (MEMS; AARDEX-USA, Ltd., Union City,
CA). Exclusion criteria were the use of a medication supply
box, preparation of medication by others than the patient,
end-stage HF or another terminal disease. At either 1, 6 or
12 months after discharge at the corresponding assessments
of COACH, patients were approached by a research assis-
tant to ask them to participate in this substudy.
Measurement of adherence: the MEMS
Adherence to ACEi/ARB was objectively measured using
the MEMS device. The MEMS is an electronic monitoring
system with a computer chip embedded in the cap of the
bottle, recording each time the cap is removed. Real-time
data were collected on the device and were transferred to a
computer at the end of the monitor period. The MEMS
bottles were filled by the patients’ local pharmacy and
patients were informed about the monitoring procedure,
the time of refilling and the number of provided tablets.
Patients were instructed to open the MEMS bottle only
when they actually took their medication and to write down
all other openings (i.e. refilling or by accident). These addi-
tional events were removed from the MEMS data prior to
analysis.
The MEMS registered the percentage of the prescribed
doses taken during the monitored period (‘taking adher-
ence’) and the percentage of days on which the patient took
the accurate, prescribed doses of medication (‘dosing adher-
ence’). Wu and colleagues found that event-free survival
was significantly better when the prescribed number of
doses taken or the percentage of days the correct number
of doses was taken was ≥88 % [13]. Therefore, also in this
study, patients were considered to be adherent when their
taking or dosing adherence was ≥88 %.
Measurement of adherence: self-report
Self-reported adherence was measured with the Revised HF
Compliance Questionnaire [14] on a five-point scale
(10‘never’; 50‘always’). Patients were considered to be
‘adherent’ when they reported that they had taken their
medication ‘always’ or ‘mostly’ during the last week, which
is confirmative with other studies [2, 14, 15]. Importance of
and difficulty with taking medication was assessed on a
similar five-point scale. Data on self-reported adherence
collected at the same moment (i.e. 1, 6 or 12 months after
discharge) that monitoring with the MEMS was started were
used for analyses.
Other study measurements
At baseline and 1, 6, and 12 months after discharge, knowl-
edge on HF and the regimen was measured with the Dutch
HF Knowledge Scale [16]. The Centre for Epidemiological
Studies Depression scale (CES-D) was used to measure the
presence of depressive symptoms (CES-D ≥16) [17] and
was completed at baseline and 12 and 18 months after
discharge. Data on HF knowledge and depressive symptoms
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collected most closely to the start of registration by MEMS
were used for analysis. At baseline, clinical variables and
demographics were collected from the patients’ medical
record and by interview.
Statistical analysis
Descriptive statistics were used to characterise the study
population and to examine medication adherence. Differ-
ences between adherent and non-adherent patients were
tested with Chi-square tests or Fisher’s exact tests for di-
chotomous variables and Mann–Whitney tests for continu-
ous variables. A P-value<.05 was considered as statistically
significant. All analyses were performed with SPSS 16.0
(SPSS Inc, Chicago, IL).
Results
A total of 263 of the patients participating in COACH were
eligible to participate in the substudy and 226 of these
patients did not meet the inclusion criteria: 137 patients
used a medication supply box, 37 patients were not pre-
scribed an ACEi or ARB, and 24 patients refused to partic-
ipate. Other reasons for exclusion were: discharge to a
nursing home (9), withdrawal from COACH (8), presence
of end-stage HF or another terminal illness (3) or other
reasons (8). The mean age of the study population (n037)
was 68±10 years, 27 % were female and 40 % were in New
York Heart Association (NYHA) functional class III-IV at
discharge, with a mean left ventricular ejection fraction
(LVEF) of 33 %±13 (Table 1). Patients were monitored by
MEMS for a mean duration of 114 days (range 54–
155 days). Thirteen patients were enrolled in the substudy
1 month after discharge; 20 patients at 6 months, and 4
patients started with monitoring at 12 months during
follow-up. Moment of enrolment and total monitored days
was not associated with adherence.
Adherence: self-report versus the MEMS
All 37 patients reported that they ‘always’ took their med-
ication as prescribed (i.e. 100 % adherence). They also
reported that taking medication was ‘(highly) important’ to
them. None of the patients reported problems with taking
medication.
When adherence was measured using the MEMS, 76 %
of all patients were adherent to their medication, since their
taking or dosing adherence was ≥88 %. In all patients, the
mean ‘taking compliance’ was 94±17 %, indicating that
94 % of the prescribed medication was taken by the patients,
although it was still possible that patients did not take the
correct dose every day. The mean ‘dosing adherence’ was
90±24 %, indicating that in 90 % of all monitored days, the
prescribed daily dose of the medication was taken. Adher-
ence to ACEi was monitored in 86 % of the study popula-
tion, adherence to ARB in 14 %. Figure 1a presents MEMS
data of a non-adherent patient who had to take his medica-
tion twice a day. This patient took his medication at many
different time points, with a wide range of intervals between
the doses taken (0.5–47.8 h). In contrast, Fig. 1b presents
data of an adherent patient (also with a ‘twice a day regi-
men’), who was more structured in taking his medication.
Non-adherent patients were more often prescribed an
ACEi/ARB 2–3 times a day instead of once a day, compared
with adherent patients (78 % vs. 21 %, P<.01). Non-
adherent patients also reported more depressive symptoms
(75 % vs. 29 %, P0.04) and had a shorter history of HF (8
vs. 41 months, P0.04). Although not statistically significant,
none of the non-adherent patients had a history of a previous
admission for HF, whereas a quarter of the adherent patients
had such a history. No differences in knowledge were found
between adherent and non-adherent patients (Table 1). Of all
patients, 13 were in the ‘care as usual’ group during follow-
up; 24 patients were in one of the intervention groups
(‘basic/intensive support’). No differences in adherence
were found between the different groups.
Discussion
This study compared self-report with objectively measured
medication adherence using an evidence-based cutpoint in
the same study population. The main result of this study is
that medication adherence objectively measured by MEMS
was remarkably lower than self-reported adherence. All
patients reported 100 % adherence, they considered taking
medication to be (very) important, and they perceived no
difficulties with taking medication. However, 1 out of 4
patients did not actually take their medication as prescribed.
Moreover, these patients were not only non-adherent, but
also had an increased risk for adverse outcomes, since
adherence was defined using an evidence-based cutpoint
(≥88 %). Two possible explanations may underlie the differ-
ences between self-reported and objectively measured ad-
herence. Firstly, patients who reported to be adherent, but
appeared to be non-adherent when measured objectively,
may be convinced that they actually took their medication
as prescribed, since forgetfulness is a prominent barrier to
adherence [8]. Secondly, patients may not want to admit that
they were non-adherent, and therefore reported to be adher-
ent. Although it is still possible that patients did open the
cap but did not actually take their medication, the MEMS
may be less vulnerable to social desirability and especially
recall problems than self-report [18], since it obtains real-
time data.
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Another aim of the study was to assess differences be-
tween adherent and non-adherent patients, based on an
evidence-based cutpoint. We confirmed that non-adherent
patients were more often prescribed a complex medication
regimen (2–3 times a day medication vs. once a day) [19].
Although patients were also prescribed medications other
that ACEi/ARB during the monitoring period, it is stated
that monitoring one medication accurately reflects adher-
ence with other medication [3]. The total number of other
medications did not affect adherence. Therefore, regarding
complexity of the regimen, we conclude that the amount of
dosages a day (2–3 times vs. once), but not the total number
of prescribed medication, affects adherence in HF patients.
Non-adherent patients also had a shorter history of HF
reflecting less routine in taking medication. A history of HF
can be an important aspect in adequate self-care [20]. In line
with this, it was found that none of the non-adherent patients
and 25 % (n07) of the adherent patients had a previous
admission for HF. This is confirmative with other studies
[21, 22] and, although not statistically significant, can be
clinically meaningful in terms of learning about the
seriousness of HF with respect to medication adherence. A
previous HF admission may result in more vigilance in
taking medication as prescribed. Furthermore, non-
adherent patients more often had depressive symptoms,
possibly due to impaired cognition, feelings of hopelessness
or lack of optimism [23, 24]. Other studies also showed that
there is an association between depressive symptoms, ad-
herence and outcome [15, 25, 26].
Although we found that self-report does not reflect the
actual adherence and more objective measurement instru-
ments are superior, there is some role for assessing adher-
ence using self-report by researchers and clinicians. When
patients report themselves to be non-adherent, this is actu-
ally often the case, since it was found that self-reported non-
adherence corresponds with objectively measured non-
adherence [10]. However, HF patients commonly overesti-
mate their medication adherence, and therefore it is sug-
gested that self-report is able to detect non-adherence, but
seems to be less sensitive for detecting adherence. There-
fore, self-reported adherence should be interpreted with
caution in clinical practice and studies [3].
Table 1 Characteristics of the study population and differences between adherent and non-adherent patients based on the MEMS (n037)
All patients (n037) Adherent patients (n028) Non-adherent patients (n09) P-value
Demographics
Age (years), mean±SD 68±10 69±9 63±10 .10
Female, % (n) 27 % (10) 29 % (8) 22 % (2) 1.00
Living alone, % (n) 30 % (11) 25 % (7) 44 % (4) .40
High educational level, % (n) 19 % (7) 25 % (7) 0 % (0) .16
Clinical variables
LVEF (%), mean±SD (n) 33±13 34±14 29±7 .40
NYHA class (discharge): III–IV % (n) 40 % (15) 43 % (12) 33 % (3) .70
Length of HF (months), mean±SD 33±54 41±59 8±22 .04
Previous HF admission, % (n) 19 % (7) 25 % (7) 0 % (0) .16
Depressive symptoms, % (n) 39 % (14) 29 % (8) 75 % (6) .04
Ischaemic HF, % (n) 35 % (13) 36 % (10) 33 % (3) 1.00
Comorbidity
Diabetes, % (n) 16 % (6) 11 % (3) 33 % (3) .14
COPD, % (n) 8 % (3) 7 % (2) 11 % (1) 1.00
Hypertension, % (n) 38 % (14) 43 % (12) 22 % (2) .43
Medication
Dosage >1 time a day, % (n) 35 % (13) 21 % (6) 78 % (7) <.01
Monitored medication: .31
- ACEi, % (n) 86 % (14) 82 % (23) 100 % (9)
- ARB, % (n) 14 % (5) 18 % (5)
Days monitored with MEMS, mean±SD 114±26 117±25 107±30 .40
Total number of medications, mean±SD 6.6±2.1 6.5±2.3 6.7±1.7 .76
HF knowledge
Total score, mean±SD 13.0±1.9 13.3±1.2 11.9±3.1 .12
ACEi angiotensin converting enzyme-inhibitor, ARB angiotensin receptor blocker, COPD chronic obstructive pulmonary disease, HF heart failure,
LVEF left ventricular ejection fraction, MEMS medication event monitoring system, NYHA New York heart association
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This study showed that medication adherence is still a
problem in HF patients, and that patients are not always as
adherent as they say. It also underlines the difficulty in really
getting a good assessment of adherence. Healthcare pro-
viders should be aware of this when discussing adherence
with their patients. Possible barriers to medication intake as
Fig. 1 aMEMS data of a patient who was prescribed lisinopril 10 mg,
twice a day. Every dot on the diagram indicates an opening of the
MEMS bottle. He was monitored for 134 days, so he had to take 268
tablets, but he took 198 tablets (taking adherence 73.8 %). Dosing
adherence was 43.4 %, indicating that he took the correct number of
tablets on 43.4 % of the monitored days. b Data of a patient who was
prescribed enalapril 5 mg, twice a day and was monitored for 149 days.
This patient had a taking adherence of 97.9 % and a dosing adherence
of 93.3 %
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prescribed (adverse side effects or practical problems, as a
result of intake of diuretics) should be addressed and health-
care providers should help patients to manage these barriers
in order to increase adherence. In case of forgetfulness,
patients should be provided with reminders or conditions
that make it less likely to forget medication (such as a
medication supply box, or assistance by homecare or phar-
macists). Changing the patients’ prescription to a ‘once a
day regimen’ is an intervention that could easily be imple-
mented in daily practice and will also help patients to
manage their complicated HF regimen. Additionally, health-
care providers should stress the importance of adherence by
focusing on possible consequences of not taking medication
at the prescribed dose.
Our study has some limitations. The first one is the small
sample size and, therefore, only univariate analyses were
performed. Another limitation is the inability to generalise
the results to the whole HF population, since patients using a
medication supply box were excluded.
Conclusion
Medication adherence objectively measured by MEMS was
remarkably lower than self-reported adherence, indicating that
self-report seems to be prone to overestimating the patients’
true adherence. All patients in the study reported to be adherent,
but 1 out of 4 patients were actually non-adherent and, there-
fore, were at an increased risk for adverse outcomes. Given the
evidence of its importance, further efforts are needed to
improve medication adherence. With respect to clinical rele-
vance, further research should focus on identifying character-
istics of patients who are non-adherent by taking less than
88 % of their prescribed medication. This can help healthcare
providers to focus on these patients and to implement educa-
tion and counselling targeted at improving adherence and,
therefore, reducing risk for adverse outcomes.
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